Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1418395 | 0.89 | HPGD (0.71) | ENPP2CA2CA9MEN1HPGD | |
| SCHEMBL6766911 | 0.82 | GAA (0.66) | ENPP2CA2CA9MEN1HPGD | |
| SCHEMBL6765613 | 0.81 | MEN1 (0.52) | CA2MEN1KMT2AL3MBTL1CA1 | |
| SCHEMBL10636593 | 0.79 | NPC1 (0.71) | CA2MEN1HPGDKMT2ACA1 | |
| SCHEMBL4239479 | 0.79 | ENPP2 (0.88) | ENPP2CA2CA9MEN1HPGD | |
| SCHEMBL7399657 | 0.78 | NPC1 (0.69) | CA2MEN1HPGDKMT2ACA1 | |
| SCHEMBL20010530 | 0.78 | KMT2A (0.88) | ENPP2CA2CA9MEN1HPGD | |
| SCHEMBL17890842 | 0.78 | PARK7 (0.48) | CA2CA9CA1CACNA1GCA12 | |
| SCHEMBL6766906 | 0.77 | NPC1 (0.46) | CA2MEN1HPGDKMT2AL3MBTL1 | |
| SCHEMBL3439592 | 0.77 | ENPP2 (1.00) | ENPP2CA2CA9MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | ENPP2 712/4885CA2 300/4885CA9 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.